Results 1 to 10 of about 41,111 (239)

A Review of the Clinical Pharmacokinetics of Polymyxin B [PDF]

Antibiotics, 2019
Polymyxin B remains an antibiotic of last resort because of its toxicities. Although newer therapies are becoming available, it is anticipated that resistance to these agents will continue to emerge, and understanding the safest and most efficacious ...
Sean N Avedissian, Jiajun Liu, Nathaniel J Rhodes   +2 more
exaly   +4 more sources

Novel Polymyxin Combination With Antineoplastic Mitotane Improved the Bacterial Killing Against Polymyxin-Resistant Multidrug-Resistant Gram-Negative Pathogens [PDF]

Frontiers in Microbiology, 2018
Due to limited new antibiotics, polymyxins are increasingly used to treat multidrug-resistant (MDR) Gram-negative bacteria, in particular carbapenem-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae.
Yohei Doi, Tony Velkov, Phillip J Bergen   +2 more
exaly   +4 more sources

Polymyxin B Nephrotoxicity: From Organ to Cell Damage. [PDF]

PLoS ONE, 2016
Polymyxins have a long history of dose-limiting toxicity, but the underlying mechanism of polymyxin B-induced nephrotoxicity is unclear. This study investigated the link between the nephrotoxic effects of polymyxin B on renal metabolic functions and ...
Maria de Fátima Fernandes Vattimo, Mirian Watanabe, Cassiane Dezoti da Fonseca, Luciana Barros de Moura Neiva, Edson Andrade Pessoa, Fernanda Teixeira Borges   +5 more
doaj   +3 more sources

Comparison of the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of ventilator-associated pneumonia caused by carbapenem-resistant gram-negative bacteria: a retrospective cohort study

Frontiers in Pharmacology, 2023
Objective: To investigate the clinical efficacy and toxicity of nebulized polymyxin monotherapy and combined intravenous and nebulized polymyxin for the treatment of VAP caused by CR-GNB.
Qiyu Wang
exaly   +3 more sources

Direct interaction between phosphotransferase LpxT and ArnT modulates polymyxin B resistance in Pseudomonas aeruginosa [PDF]

Microbiology Spectrum
Pseudomonas aeruginosa is a common human opportunistic pathogen that causes a variety of acute and chronic infections. Polymyxins are considered last-resort options for treating serious infections caused by multidrug-resistant gram-negative bacteria ...
Yuxi Bai, Yue Zhao, Yuerong Yuan, Fang Bai, Zhihui Cheng, Weihui Wu, Un-Hwan Ha, Shouguang Jin, Yongxin Jin   +8 more
doaj   +2 more sources

Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case–control study

Annals of Intensive Care, 2022
Background The mortality of extensively drug-resistant Gram-negative (XDR GN) bacilli-induced ventilator-associated pneumonia (VAP) is extremely high. The purpose of this study was to compare the efficacy and safety of inhaled (IH) plus intravenous (IV ...
Jiao Liu, Min Shao, Qianghong Xu, Fen Liu, Xiaojun Pan, Jianfeng Wu, Lihong Xiong, Yueming Wu, Mi Tian, Jianying Yao, Sisi Huang, Lidi Zhang, Yizhu Chen, Sheng Zhang, Zhenliang Wen, Hangxiang Du, TaoWang, Yongan Liu, Wenzhe Li, Yan Xu, Jean-louis Teboul, Dechang Chen   +21 more
doaj   +1 more source

Comparative Proteomics of Outer Membrane Vesicles from Polymyxin-Susceptible and Extremely Drug-Resistant Klebsiella pneumoniae

mSphere, 2023
Outer membrane vesicles (OMVs) secreted by Gram-negative bacteria serve as transporters for the delivery of cargo such as virulence and antibiotic resistance factors.
Maytham Hussein, Raad Jasim, Hakan Gocol, Mark Baker, Varsha J. Thombare, James Ziogas, Aayush Purohit, Gauri G. Rao, Jian Li, Tony Velkov   +9 more
doaj   +1 more source

Efficacy and safety of polymyxin B in carbapenem-resistant gram-negative organisms infections

BMC Infectious Diseases, 2021
Objective To investigate how to use polymyxin B rationally in order to produce the best efficacy and safety in patients with carbapenem-resistant gram-negative organisms (CRO) infection. Methods The clinical characteristics and microbiological results of
G. L. Xia, R. L. Jiang
doaj   +1 more source

Inappropriate Doses of Intravenous Polymyxin B after Renal Adjustment Lead to Treatment Failure

Brazilian Journal of Pharmaceutical Sciences, 2021
Sub-therapeutic doses, shorter duration of therapy, female gender, bacteremia, and renal impairment were among independent predictors of polymyxin B treatment failure.
Bahiah Ismail, Mohd Nazri Shafei, Azian Harun, Saedah Ali, Mahamarowi Omar, Zakuan Zainy Deris   +5 more
doaj   +1 more source

Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy

Scientific Reports, 2021
The emergence of polymyxin resistance in Gram-negative bacteria infections has motivated the use of combination therapy. This study determined the mutant selection window (MSW) of polymyxin B alone and in combination with meropenem and fosfomycin against
Nayara Helisandra Fedrigo, Danielle Rosani Shinohara, Josmar Mazucheli, Sheila Alexandra Belini Nishiyama, Floristher Elaine Carrara-Marroni, Frederico Severino Martins, Peijuan Zhu, Mingming Yu, Sherwin Kenneth B. Sy, Maria Cristina Bronharo Tognim   +9 more
doaj   +1 more source